| 2025-05-05 | -0.41 % |
|
| 2025-05-02 | -0.9 % |
|
| 2025-05-01 | -2.45 % |
|
| 2025-04-29 | +1.93 % |
|
| 2025-04-28 | +0.8 % |
|
| 2025-04-25 | +0.36 % |
|
| 2025-04-24 | +0.7 % |
|
| 2025-04-23 | -0.18 % |
|
| 2025-04-21 | -1.3 % |
|
| 2025-04-17 | -1.89 % |
|
| 2025-04-16 | -4.29 % |
|
| 2025-04-07 | -1.6 % |
|
| 2025-04-02 | -0.4 % |
|
| 2025-04-01 | -1.49 % |
|
| 2025-03-31 | +1.5 % |
|
| 2025-03-27 | +0.02 % |
|
| 2025-03-26 | -0.37 % |
|
| 2025-03-25 | -2.39 % |
|
| 2025-03-24 | -0.53 % |
|
| 2025-03-21 | +0.32 % |
|
| 2025-03-14 | +0.34 % |
|
| 2025-03-11 | -2.59 % |
|
| 2025-03-10 | +0.77 % |
|
| 2025-03-06 | +0.39 % |
|
| 2025-03-04 | +0.45 % |
|
| 2025-02-27 | -0.18 % |
|
| 2025-02-25 | +1.91 % |
|
| 2025-02-24 | +2.21 % |
|
| 2025-02-14 | -1.96 % |
|
| 2025-02-12 | -0.54 % |
|
| 2025-02-10 | +0.43 % |
|
| 2025-02-07 | -1.42 % |
|
| 2025-02-05 | +6.5 % |
|
| 2025-02-03 | +1.21 % |
|
| 2025-01-31 | +0.49 % |
|
| 2025-01-27 | +2.73 % |
|
| 2025-01-24 | -0.89 % |
|
| 2025-01-21 | +0.99 % |
|
| 2025-01-16 | +0.18 % |
|
| 2025-01-15 | +0.69 % |
|
| 2025-01-14 | -1.14 % |
|
| 2025-01-13 | +3.04 % |
|
| 2025-01-10 | -0.75 % |
|
| 2025-01-07 | +1.34 % |
|
| 2025-01-06 | -1.01 % |
|
| 2025-01-03 | +0.75 % |
|
| 2025-01-02 | -0.52 % |
|
| 2024-12-26 | -0.5 % |
|
| 2024-12-17 | -0.21 % |
|
| 2024-12-13 | -1.26 % |
|
| 2024-12-12 | +0.24 % |
|
| 2024-12-10 | -0.68 % |
|
| 2024-12-09 | +1.85 % |
|
| 2024-12-05 | -1.41 % |
|
| 2024-12-04 | -0.02 % |
|
| 2024-12-03 | +0.08 % |
|
| 2024-12-02 | -1.69 % |
|
| 2024-11-26 | -4.76 % |
- Amgen (AMGN) stock dropped 4.76% due to disappointing results from a mid-stage trial of its weight loss drug, MariTide, which showed lower-than-expected patient weight loss outcomes compared to Wall Street projections.
- Amgen (AMGN) stock fell 4.76% after the company reported mid-stage trial results for its weight loss drug MariTide, which, despite showing a 20% average weight loss over 52 weeks, failed to meet Wall Street's expectations of a higher efficacy compared to competing medications. The stock decline is attributed to the trial results being at the lower end of market expectations when investors were hoping for a greater weight loss percentage from the treatment.
- Amgen (AMGN) stock fell by nearly 8% due to disappointing trial results for its experimental weight-loss drug MariTide, which did not meet investor expectations for effectiveness.
- Amgen Inc (AMGN) stock dropped 4.76% following the release of disappointing Phase 2 study data for its obesity treatment MariTide, which showed only up to 20% average weight loss in obese patients.
- Amgen (AMGN) stock fell by 4.76% following the announcement of positive but preliminary results from a clinical trial of its experimental obesity drug, MariTide, which has yet to undergo further trials and receive FDA approval, leading to uncertainty about its future market performance.
- Amgen (AMGN) stock declined by 4.76% following the announcement of positive Phase 2 clinical trial results for its investigational obesity treatment MariTide, possibly due to investors' concerns about market competition and the need for further validation in Phase 3 trials despite the promising data.
|
| 2024-11-25 | -0.18 % |
|
| 2024-11-21 | +0.71 % |
|
| 2024-11-20 | +2.83 % |
|
| 2024-11-19 | +0.43 % |
|
| 2024-11-18 | -1.71 % |
|
| 2024-11-15 | -4.16 % |
|
| 2024-11-13 | +0.87 % |
|
| 2024-11-12 | -7.14 % |
|
| 2024-11-11 | -1.07 % |
|
| 2024-11-08 | +1.05 % |
|
| 2024-11-06 | +0.78 % |
|
